by The global cannabis pharmaceuticals market size was valued at USD 940.5 million in 2020, and is predicted to be worth around USD 130.1 billion by 2030, registering a CAGR of 105.4% during the forecast period 2022 to 2030.
Download Exclusive Sample of Report@ https://www.visionresearchreports.com/report/sample/39112
Table of Contents
Cannabis Pharmaceuticals Market Growth Factors
Rapid growth in applications of cannabis for various indications including pain, inflammation, sleep disorders, anorexia, epilepsy, schizophrenia, and multiple sclerosis is estimated to drive market growth. There is a shift from cannabis herbal preparations to prescription drugs. Demand for processed, quantified, and packaged cannabis products is significantly increasing. Moreover, consumer, as well as regulatory acceptance of cannabis products, is increasing which in turn is positively impacting market growth.
Regulatory acceptance of cannabis products such as Sativex and Epidiolex are improving patient and physician perspectives on cannabis as these drugs are developed and regulated by the stringent process.
The increasing number of research and development activities and clinical trials for studying the therapeutic benefits of cannabis will drive the market growth during the forecast period.
Cannabis Pharmaceuticals Market Report Coverage
| Report Scope | Details |
| Market Size | US$ 130.1 billion by 2030 |
| Growth Rate | CAGR of 105.4% From 2022 to 2030 |
| Largest Market | Europe |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segments Covered | Brand Type |
| Regional Scope | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Companies Mentioned | GW Pharmaceuticals, plc, Insys Therapeutics, Abbvie, Valeant Pharmaceuticals (Bausch Health Companies, Inc.) |
By Brand Type Analysis
The Epidiolex segment dominated the market for cannabis pharmaceuticals accounted for the largest revenue share in 2021 and is estimated to be the fastest-growing segment during the forecast period.
The Sativex segment is estimated to witness a CAGR of 26.9% during the forecast period. Sativex is used to treat muscle spasticity due to multiple sclerosis. Increasing demand for Sativex for use in muscle spasticity in Canada, and European countries are driving the segment growth.
By Regional Analysis
Europe dominated the market for cannabis pharmaceuticals and accounted for the highest revenue share of 43.8% in 2021. This is attributed to increasing cannabis consumption, as well as rising awareness and positive attitude towards cannabis and its products.
Cannabis cultivation in the African region is rapidly growing. Several countries such as Lesotho, South Africa, Malawi, Zambia, Rwanda, and Ghana among others have legalized medical cannabis cultivation. This in turn is estimated to drive the market in the region.
Read also @ Fitness App Market Impressive Gains by 2022-2030
Major Key Players Covered in The Cannabis Pharmaceuticals Market Report include
- GW Pharmaceuticals, plc
- Insys Therapeutics
- Abbvie
- Valeant Pharmaceuticals (Bausch Health Companies, Inc.)
Cannabis Pharmaceuticals Market Segmentation
- By Brand Type
- Sativex
- Epidiolex
- Regional
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- Italy
- France
- Netherland
- Poland
- Croatia
- Czech Republic
- Switzerland
- Asia Pacific
- Japan
- South Korea
- Australia
- New Zealand
- Latin America
- Brazil
- Mexico
- Argentina
- Columbia
- Uruguay
- Chile
- Peru
- Middle East & Africa
- Israel
- North America
Table of Contents
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Cannabis pharmaceuticals Market, By Brand Type
7.1. Cannabis pharmaceuticals Market, by Brand Type, 2021-2030
7.1.1. Sativex
7.1.1.1. Market Revenue and Forecast (2019-2030)
7.1.2. Epidiolex
7.1.2.1. Market Revenue and Forecast (2019-2030)
Chapter 8. Global Cannabis pharmaceuticals Market, Regional Estimates and Trend Forecast
8.1. North America
8.1.1. Market Revenue and Forecast, by Brand Type (2019-2030)
8.1.2. U.S.
8.1.3. Rest of North America
8.1.3.1. Market Revenue and Forecast, by Brand Type (2019-2030)
8.2. Europe
8.2.1. Market Revenue and Forecast, by Brand Type (2019-2030)
8.2.2. UK
8.2.2.1. Market Revenue and Forecast, by Brand Type (2019-2030)
8.2.3. France
8.2.3.1. Market Revenue and Forecast, by Brand Type (2019-2030)
8.2.4. Rest of Europe
8.2.4.1. Market Revenue and Forecast, by Brand Type (2019-2030)
8.3. APAC
8.3.1. Market Revenue and Forecast, by Brand Type (2019-2030)
8.3.2. India
8.3.2.1. Market Revenue and Forecast, by Brand Type (2019-2030)
8.3.3. China
8.3.3.1. Market Revenue and Forecast, by Brand Type (2019-2030)
8.3.4. Japan
8.3.4.1. Market Revenue and Forecast, by Brand Type (2019-2030)
8.3.5. Rest of APAC
8.3.5.1. Market Revenue and Forecast, by Brand Type (2019-2030)
8.4. MEA
8.4.1. Market Revenue and Forecast, by Brand Type (2019-2030)
8.4.2. GCC
8.4.2.1. Market Revenue and Forecast, by Brand Type (2019-2030)
8.4.3. North Africa
8.4.3.1. Market Revenue and Forecast, by Brand Type (2019-2030)
8.4.4. South Africa
8.4.4.1. Market Revenue and Forecast, by Brand Type (2019-2030)
8.4.5. Rest of MEA
8.4.5.1. Market Revenue and Forecast, by Brand Type (2019-2030)
8.5. Latin America
8.5.1. Market Revenue and Forecast, by Brand Type (2019-2030)
8.5.2. Brazil
8.5.2.1. Market Revenue and Forecast, by Brand Type (2019-2030)
8.5.3. Rest of LATAM
8.5.3.1. Market Revenue and Forecast, by Brand Type (2019-2030)
Chapter 9. Company Profiles
9.1. GW Pharmaceuticals, plc
9.1.1. Company Overview
9.1.2. Product Offerings
9.1.3. Financial Performance
9.1.4. Recent Initiatives
9.2. Insys Therapeutics
9.2.1. Company Overview
9.2.2. Product Offerings
9.2.3. Financial Performance
9.2.4. Recent Initiatives
9.3. Abbvie
9.3.1. Company Overview
9.3.2. Product Offerings
9.3.3. Financial Performance
9.3.4. Recent Initiatives
9.4. Valeant Pharmaceuticals (Bausch Health Companies, Inc.)
9.4.1. Company Overview
9.4.2. Product Offerings
9.4.3. Financial Performance
9.4.4. Recent Initiatives
Chapter 10. Research Methodology
10.1. Primary Research
10.2. Secondary Research
10.3. Assumptions
Chapter 11. Appendix
11.1. About Us
11.2. Glossary of Terms
Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/39112
Contact Us:
Vision Research Reports
Call: +1 9197 992 333
